Peripheral spondyloarthritis is a form of inflammatory arthritis that mainly affects joints in the arms and legs, along with tendons and ligaments, causing pain, swelling, and stiffness that can significantly impact daily life.

Understanding Treatment Goals for Peripheral Spondyloarthritis

When someone is diagnosed with peripheral spondyloarthritis, the main focus of treatment is to manage symptoms, reduce inflammation, and preserve quality of life. This condition causes arthritis (joint inflammation), enthesitis (inflammation where tendons and ligaments attach to bones), and sometimes dactylitis (swelling of entire fingers or toes, creating a sausage-like appearance). The goals of care include controlling pain, reducing swelling in affected joints, preventing joint damage, and helping people maintain their ability to work and participate in activities they enjoy.^[1][3]

Treatment approaches vary depending on which joints are affected and how severe the symptoms are. Some people experience pain in large joints like the knees, while others have problems in smaller joints of the hands and feet. The pattern of joint involvement helps doctors decide which treatments might work best. What works well for one person may not be as effective for another, so treatment plans are personalized based on individual needs and how the body responds to different therapies.^[4][8]

Medical societies and healthcare organizations have developed guidelines to help doctors choose the most appropriate treatments. These recommendations are based on research studies and clinical experience. However, the field continues to evolve as researchers discover new ways to manage this condition. Alongside standard approved medications, there are ongoing clinical trials testing innovative therapies that may offer new options for patients who don’t respond well to current treatments.^[10][11]

Standard Treatment Approaches

The first line of treatment for peripheral spondyloarthritis typically involves nonsteroidal anti-inflammatory drugs, commonly called NSAIDs. These medications work by reducing inflammation and relieving pain. Doctors usually prescribe the lowest effective dose because NSAIDs can have side effects, especially when used long-term. Common NSAIDs include medications like ibuprofen and naproxen. Patients taking NSAIDs need regular monitoring because these drugs can affect the stomach, kidneys, and cardiovascular system. If one NSAID doesn’t provide adequate relief after two to four weeks, doctors may try a different one.^[4][8][12]

When NSAIDs alone are not sufficient, particularly in cases involving multiple joints or persistent inflammation in a single joint, doctors may add disease-modifying antirheumatic drugs (DMARDs). Two DMARDs commonly used for peripheral spondyloarthritis are methotrexate and sulfasalazine. These medications work differently than NSAIDs—they target the underlying immune system processes that cause inflammation. It’s important to note that these medications are effective for peripheral joint involvement but do not help with spinal inflammation if that is also present.^[4][8]

For people with inflammation in a single joint that is not progressing to multiple joints, doctors may recommend corticosteroid injections directly into the affected joint. These injections can provide rapid relief by reducing inflammation in a specific area. Corticosteroids can also be given as oral medications for short-term use to help manage flare-ups, but long-term use is generally avoided because of potential side effects including bone thinning, weight gain, elevated blood sugar, and increased infection risk.^[12]

When first-line treatments do not provide adequate symptom control, doctors typically move to biologic medications. The most commonly used biologics for peripheral spondyloarthritis are TNF inhibitors (tumor necrosis factor inhibitors). These are injectable or infused medications that block a specific protein called TNF that promotes inflammation in the body. TNF inhibitors have been shown to be effective in reducing joint pain and swelling in peripheral spondyloarthritis. However, for patients with non-psoriatic peripheral spondyloarthritis (meaning they don’t have the skin condition psoriasis), these medications are often used off-label, meaning they are not officially approved for this specific indication. This can create challenges with insurance coverage and reimbursement in some countries.^[3][13]

Another class of biologic medications approved for treating peripheral spondyloarthritis includes IL-17A inhibitors. These drugs work by blocking interleukin-17A, another protein involved in the inflammatory process. Like TNF inhibitors, IL-17A inhibitors are given by injection. Drug development in this area continues, with pharmaceutical companies working to create new biologics with different mechanisms of action.^[4][8]

Physical therapy plays an important supporting role in managing peripheral spondyloarthritis. While medications address inflammation and pain, physical therapy helps maintain joint function and muscle strength. A physical therapist can design an exercise program tailored to which joints are affected. This might include stretching exercises to maintain flexibility, strengthening exercises to support joints, and techniques to protect joints during daily activities. Regular exercise is particularly important because prolonged inactivity can lead to stiffness and muscle weakness, which can worsen symptoms.^[4][8]

The duration of treatment varies considerably from person to person. Some people need to take medications continuously to keep symptoms under control, while others may be able to reduce or stop treatment after achieving remission. Regular follow-up appointments are essential so doctors can monitor disease activity, adjust medications as needed, and watch for side effects. Blood tests may be performed periodically to check for inflammation markers and to ensure medications are not affecting liver or kidney function.^[12]

Innovative Treatments Being Tested in Clinical Trials

Clinical research into peripheral spondyloarthritis has expanded significantly in recent years, with multiple studies testing new treatment approaches. One particularly interesting area of research involves using TNF inhibitors in early-stage disease. A study called CRESPA examined whether the TNF inhibitor golimumab could potentially reverse disease in people who had recently developed symptoms.^[13]

In the CRESPA trial, researchers enrolled patients who had peripheral spondyloarthritis with symptoms lasting fewer than 12 weeks—meaning their disease was caught very early. Participants received 50 milligrams of golimumab injected under the skin every four weeks. The study was designed with a randomized, placebo-controlled phase where some patients received the active drug while others received an inactive placebo. This type of design helps researchers determine whether the drug truly has an effect beyond what might occur naturally.^[13]

The results were remarkable. Eighty-two percent of patients treated with golimumab achieved sustained clinical remission, meaning they had complete absence of peripheral arthritis, enthesitis, and dactylitis maintained at consecutive visits. In contrast, patients who received placebo did not show significant improvement, ruling out the possibility of spontaneous remission. Even more encouraging, when researchers followed patients long-term—ranging from 23 months to five years after stopping the medication—53 percent remained in sustained, drug-free remission. This suggests that early aggressive treatment with biologics might fundamentally change the disease course in some patients.^[13]

Importantly, the CRESPA study also identified factors that predicted whether someone would maintain remission after stopping treatment. Patients with polyarticular disease (inflammation in many joints) and those with pre-existing psoriasis were more likely to experience disease relapse after discontinuing golimumab. Patients with psoriasis had 80 percent lower odds of maintaining drug-free remission, and those with polyarticular disease had 83 percent lower odds. This information helps doctors identify which patients might benefit from continuing treatment long-term versus those who might be able to stop medication.^[13]

Clinical trials typically proceed through three phases. Phase I trials focus primarily on safety, usually involving small numbers of participants to determine whether a drug causes unacceptable side effects and to establish appropriate dosing. Phase II trials enroll more patients and begin to assess whether the treatment actually improves disease symptoms or markers. These studies provide preliminary evidence of efficacy. Phase III trials are the largest and compare the new treatment directly to standard therapy or placebo in hundreds or thousands of patients. These trials provide the definitive evidence needed for regulatory approval by agencies like the U.S. Food and Drug Administration or the European Medicines Agency.^[13]

Beyond TNF inhibitors, researchers are exploring other molecular targets for treating peripheral spondyloarthritis. The success of IL-17A inhibitors has opened the door to investigating additional components of the immune system that might be involved in disease. Drug development efforts continue to identify new molecules that could offer alternatives for patients who don’t respond to currently available biologics.^[4][8]

Clinical trials for peripheral spondyloarthritis are conducted in multiple countries including Poland, various European nations, and the United States. Patient eligibility for trials varies depending on the specific study design. Generally, trials look for patients who meet specific criteria such as disease duration, severity of symptoms, whether they have or haven’t tried certain medications, and whether they have specific types of peripheral spondyloarthritis (such as with or without psoriasis). People interested in participating in clinical trials can discuss options with their rheumatologist or search clinical trial registries to find studies recruiting participants in their area.^[13]

One challenge in clinical research on peripheral spondyloarthritis is that this condition has been relatively neglected compared to other forms of spondyloarthritis. Most research has focused on ankylosing spondylitis (which primarily affects the spine) or psoriatic arthritis (which involves both skin and joint symptoms). As a result, patients with non-psoriatic peripheral spondyloarthritis represent an emerging group that lacks specific treatment recommendations and remains poorly characterized in the medical literature. This makes ongoing clinical research particularly important for developing evidence-based treatment guidelines.^[3]

Most common treatment methods

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • First-line treatment prescribed at the lowest effective dose to reduce pain and inflammation
  • If one NSAID doesn’t work after two to four weeks, a different NSAID may be tried
  • Requires monitoring due to potential effects on stomach, kidneys, and cardiovascular system
• Disease-Modifying Antirheumatic Drugs (DMARDs)
  • Methotrexate and sulfasalazine are commonly used for peripheral joint inflammation
  • Target underlying immune system processes causing inflammation
  • Effective for peripheral arthritis but not for spinal inflammation
• Corticosteroid Treatment
  • Injections directly into inflamed joints for nonprogressive single joint involvement
  • Short-term oral corticosteroids may be used instead of NSAIDs during flare-ups
  • Long-term use avoided due to side effects including bone thinning and weight gain
• Biologic Medications
  • TNF inhibitors block tumor necrosis factor protein to reduce inflammation
  • IL-17A inhibitors block interleukin-17A, another inflammatory protein
  • Used when first-line treatments don’t provide adequate symptom control
  • Often used off-label for non-psoriatic peripheral spondyloarthritis
• Physical Therapy
  • Helps maintain joint function and muscle strength
  • Includes stretching exercises for flexibility and strengthening exercises to support joints
  • Teaches techniques to protect joints during daily activities